Smith LT, et al. PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood. 1996;88(4):1234–47.

Article  CAS  PubMed  Google Scholar 

Hohaus S, et al. PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene. Mol Cell Biol. 1995;15(10):5830–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho PA, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group. Blood. 2009;113(26):6558–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Staffas A, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118(22):5905–13.

Article  CAS  PubMed  Google Scholar 

Liang DC, et al. CEBPalpha mutations in childhood acute myeloid leukemia. Leukemia. 2005;19(3):410–4.

Article  CAS  PubMed  Google Scholar 

Hollink IH, et al. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia. Haematologica. 2011;96(3):384–92.

Article  CAS  PubMed  Google Scholar 

Matsuo H, et al. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Blood Cancer J. 2014;4: e226.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Y, et al. Companion gene mutations and their clinical significance in AML with double mutant CEBPA. Cancer Gene Ther. 2020;27(7–8):599–606.

Article  CAS  PubMed  Google Scholar 

Taskesen E, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469–75.

Article  CAS  PubMed  Google Scholar 

Fasan A, et al. The role of different genetic subtypes of CEBPA mutated AML. Leukemia. 2014;28(4):794–803.

Article  CAS  PubMed  Google Scholar 

Green CL, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28(16):2739–47.

Article  CAS  PubMed  Google Scholar 

Wakita S, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022;6(1):238–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taube F, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139(1):87–103.

Article  CAS  PubMed  Google Scholar 

Tarlock K, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group. Blood. 2021;138(13):1137–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wouters BJ, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pabst T, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3):263–70.

Article  CAS  PubMed  Google Scholar 

Dufour A, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570–7.

Article  CAS  PubMed  Google Scholar 

Tawana K, et al. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood. 2015;126(10):1214–23.

Article  CAS  PubMed  Google Scholar 

Khoury JD, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022;36(7): 1703–1719.

Arber DA, et al. Classification of myeloid neoplasms/acute leukemia: global perspectives and the international consensus classification approach. Am J Hematol. 2022;97(5):514–8.

Article  PubMed  PubMed Central  Google Scholar 

Gombart AF, et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood. 2002;99(4):1332–40.

Article  CAS  PubMed  Google Scholar 

Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4(5):394–400.

Article  CAS  PubMed  Google Scholar 

Fitzgibbon J, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 2005;65(20):9152–4.

Article  CAS  PubMed  Google Scholar 

Wouters BJ, et al. Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia. Leukemia. 2007;21(11):2382–4.

Article  CAS  PubMed  Google Scholar 

Mannelli F, et al. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Haematologica. 2017;102(3):529–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tien FM, et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA. Haematologica. 2018;103(11):e510–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahn JS, et al. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. Ann Hematol. 2016;95(2):301–10.

Article  CAS  PubMed  Google Scholar 

Dufour A, et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol. 2012;91(7):1051–63.

Article  PubMed  Google Scholar 

Hou HA, et al. Reply to ‘Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis.’ Br J Cancer. 2009;101(4):738–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin LI, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005;11(4):1372–9.

Article  CAS  PubMed  Google Scholar 

Bacher U, et al. Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity. Blood. 2012;119(20):4719–22.

Article  CAS  PubMed  Google Scholar 

Frohling S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22(4):624–33.

Article  PubMed  Google Scholar 

Pabst T, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009;100(8):1343–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues Revised. 4th ed. Lyon: IARC; 2017.

Google Scholar 

Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.

Article  PubMed  PubMed Central  Google Scholar 

Renneville A, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood. 2009;113(21):5090–3.

Article  CAS  PubMed  Google Scholar 

Fasan A, et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia. 2013;27(2):482–5.

Article  CAS  PubMed